Randomized controlled trial of landiolol, a short-acting beta-1 adrenergic receptor blocker, illustrating changes in high-molecular weight adiponectin levels after elective percutaneous coronary intervention

Heart and Vessels
Masayoshi KiyokuniKazuo Kimura

Abstract

Adiponectin (APN) has cardioprotective properties and bisoprolol has been reported to increase myocardial APN expression and reduce myocardial damage. Administration of landiolol, which has a higher cardio-selectivity and shorter half-life than bisoprolol, during the percutaneous coronary intervention (PCI) may increase serum APN and high-molecular weight (HMW)-APN, an active form of APN, in patients with stable angina pectoris (SAP). We recruited 70 patients with SAP and randomized them to intravenous landiolol during PCI (N = 35) or control group (N = 35). The primary endpoint was serum APN and HMW-APN level 3 days after PCI. There was no difference in the primary endpoint between the landiolol and control groups (8.93 ± 5.24 vs. 10.18 ± 5.81 μg/mL, p = 0.35 and 3.36 ± 2.75 vs. 4.28 ± 3.13 μg/mL, p = 0.20) for APN and HMW-APN levels, respectively. APN and HMW-APN level were significantly decreased 1 day after PCI [-0.55 ± 0.92 μg/mL (9.87-9.32 μg/mL), p < 0.001 and -0.20 ± 0.45 μg/mL (3.89-3.69 μg/mL), p < 0.001, respectively]. Additionally, the absolute change in HMW-APN was significantly smaller in the landiolol group compared to the control group (-0.08 ± 0.27 vs. -0.31 ± 0.55 μg/mL, p = 0.031). Multiple linear regression ...Continue Reading

References

Jun 1, 1992·Chemical & Pharmaceutical Bulletin·S IguchiM Kawamura
May 27, 2005·International Journal of Obesity : Journal of the International Association for the Study of Obesity·V MerlB Schultes
Nov 17, 2007·Journal of Anesthesia·Saori Kimura-KurosawaAkiyoshi Namiki
Apr 3, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Seiichi MatsuoUNKNOWN Collaborators developing the Japanese equation for estimated GFR
Aug 28, 2009·International Journal of Cardiology·Haengnam ParkToshiji Iwasaka
Feb 18, 2011·Canadian Journal of Physiology and Pharmacology·Song ZhangGeorge Ruiz
Jun 22, 2017·International Journal of Molecular Sciences·Arunkumar E Achari, Sushil K Jain
Oct 3, 2018·Aging and Disease·Stefano RizzaMassimo Federici
Mar 29, 2019·Eastern Mediterranean Health Journal = La Revue De Santé De La Méditerranée Orientale = Al-Majallah Al-ṣiḥḥīyah Li-sharq Al-mutawassiṭ·Gummanur ManjunathShyju Varghese

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.